Life sciences venture capital company Sofinnova has launched a new strategy in digital medicine, accompanied by a series of investments in start-ups operating within the c
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh